Shingles vaccine lowers risk of dementia

Pharma News: A recombinant shingles vaccine which was added to Australia’s National Immunisation Program (NIP) in November last year, is linked with a larger reduction in risk of dementia than the previous shingles vaccine, according to new research.

Shingles is a painful and serious condition afflicting many elderly people. It is caused by the Herpes zoster virus that can flare up in people who previously had chicken pox.

There has been emerging evidence that a shingles vaccine might protect against dementia, but much of the current data is based on the older vaccine, MSD’s Zostravax, which has now been discontinued in many countries in favour of a recombinant vaccine.

This new study showed GSK’s Shingrix was associated with 17% lower risk of dementia than Zostavax, and 23-27% less than with the other vaccines. This equates to 5-9 more months lived without dementia for those who had been given the Shingrix vaccine compared to the other vaccines. The beneficial effects were present in both sexes but greater in women than in men.

Dr Maxime Taquet, NIHR Academic Clinical Lecturer in the Department of Psychiatry at Oxford, who led the study said “The size and nature of this study makes these findings convincing, and should motivate further research. They support the hypothesis that vaccination against shingles might prevent dementia. If validated in clinical trials, these findings could have significant implications for older adults, health services, and public health.”

John Todd, Professor of Precision Medicine at the University of Oxford’s Nuffield Department of Medicine, said “A key question is, how does the vaccine produce its apparent benefit in protecting against dementia? One possibility is that infection with the Herpes zoster virus might increase the risk of dementia, and therefore by inhibiting the virus the vaccine could reduce this risk. Alternatively, the vaccine also contains chemicals which might have separate beneficial effects on brain health.”

In many countries, including the UK and USA, Zostavax has now been withdrawn and replaced by a much more effective vaccine (Shingrix). In the UK, Shingrix is being offered by the NHS to all elderly people and certain other groups.

In the new study, researchers at the University of Oxford and NIHR OH BRC used the USA TriNetX electronic health records network. In the USA, there was a switchover between Zostavax and Shingrix in October 2017. This allowed the researchers to compare the risk of dementia in the six years following Shingrix compared to otherwise similar people who had received Zostavax. More than 100,000 people were in each group. Shingrix was also compared to people who had received vaccines against other infections (flu and tetanus, diphtheria, and pertussis).

Paul Harrison, Professor of Psychiatry and OH BRC Theme lead for Molecular Targets, who supervised the study, said “The findings are intriguing and encouraging. Anything that might reduce the risk of dementia is to be welcomed, given the large and increasing number of people affected by it.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.